Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Simbolis: 002399.SZ
SHZ
9.37
CNYRinkos kaina šiandien
-17.2720
P/E santykis
-0.4195
PEG koeficientas
12.33B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10139.37 | 2265.8 | 3450.4 | 3925.4 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 1631.92 | 414.2 | 1311.6 | 981.2 | ||||||||||||||||||
balance-sheet.row.net-receivables | 6253.86 | 1528.6 | 1946.6 | 1985.5 | ||||||||||||||||||
balance-sheet.row.inventory | 30150.6 | 6654.1 | 6843.9 | 4707.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 857.6 | 155.4 | 148.7 | 151.2 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 47401.43 | 10603.9 | 12389.6 | 10769.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10261.67 | 2634.2 | 2477.3 | 2537.2 | ||||||||||||||||||
balance-sheet.row.goodwill | 9504.81 | 2322.4 | 2351 | 2152.2 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 2153.33 | 493.2 | 571.7 | 586.7 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11658.14 | 2815.6 | 2922.6 | 2738.9 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 8198.95 | 2514.9 | 1152.5 | 1636.7 | ||||||||||||||||||
balance-sheet.row.tax-assets | 753.39 | 320.5 | 139.6 | 121.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 2460.85 | 314.3 | 1732.5 | 1304.1 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 33333 | 8599.5 | 8424.6 | 8338.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.account-payables | 1374.71 | 302.2 | 427.4 | 385.8 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 14923.61 | 3662.4 | 4056.5 | 3299.9 | ||||||||||||||||||
balance-sheet.row.tax-payables | 525.27 | 157.2 | 141.8 | 158.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 8990.3 | 1810 | 2407.4 | 2354.3 | ||||||||||||||||||
Deferred Revenue Non Current | 127.65 | 30.4 | 32.5 | 16.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1232.54 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 3123.05 | 655.4 | 658 | 3.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 10620.06 | 2198 | 2830.8 | 2793.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 383.85 | 90.4 | 110.7 | 104 | ||||||||||||||||||
balance-sheet.row.total-liab | 31250.86 | 7184.2 | 8406.6 | 7584.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 14530.6 | 1543.2 | 4314.1 | 3647 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9077.94 | 1373.8 | 843.4 | 563.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 19614.97 | 7528.9 | 5686.1 | 5733.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49092.69 | 11913.1 | 12310.9 | 11411.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.minority-interest | 360.05 | 75.2 | 96.7 | 112 | ||||||||||||||||||
balance-sheet.row.total-equity | 49452.73 | 11988.4 | 12407.6 | 11523.3 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 80734.43 | - | - | - | ||||||||||||||||||
Total Investments | 9830.87 | 2929.1 | 2464.1 | 2617.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 24004.33 | 5562.8 | 6463.9 | 5654.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 15496.87 | 3711.2 | 4325.1 | 2709.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -783.26 | -783.3 | 714.7 | 233.4 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 371.05 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -237.6 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -1332.4 | 43.3 | 0.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | -349.12 | -563.1 | -2311.3 | -1125.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 270.55 | 270.5 | -176.1 | 141.8 | ||||||||||||||||||
cash-flows.row.inventory | -619.67 | -619.7 | -2151.6 | -1520.2 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -213.9 | 59.7 | 423.9 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 548.74 | 3003.1 | 532.3 | 752.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 678.73 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 2.34 | -4.9 | 0 | 1.7 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -677.26 | -758.2 | -4482.7 | -2370.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1647.35 | 2349.3 | 4210.7 | 3305.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 694.02 | -0.1 | 744.2 | -22.9 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1221.57 | 1141.2 | 249.8 | 719.9 | ||||||||||||||||||
cash-flows.row.debt-repayment | -5991.71 | -730.9 | -6036.3 | -3730.6 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -425.89 | -146.7 | -251 | -412.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 5207.43 | -325.4 | 6616.8 | 3642 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1210.17 | -1203 | 329.6 | -501.1 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 36.32 | 36.3 | 17.3 | -62.8 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 445.94 | -287.1 | -159.9 | 149.4 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6714.63 | 1851.6 | 1319.7 | 1479.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6268.69 | 2138.8 | 1479.6 | 1330.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 678.73 | 471.4 | -756.6 | -6.6 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 233.86 | 26.5 | -979 | -200.5 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5434.47 | 5421.7 | 7159.4 | 6365.2 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 3670.52 | 3746.3 | 4825 | 4332.1 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1763.95 | 1675.4 | 2334.4 | 2033 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 179.91 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 458.57 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 2128.44 | 1935.4 | 1211.9 | 1068.9 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5798.96 | 5681.6 | 6036.9 | 5401 | ||||||||||||||||||
income-statement-row.row.interest-income | -39.52 | -39.5 | 54.1 | 54.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 241.34 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -433.09 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -674.43 | -259.9 | 1135.1 | 773.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -763.62 | -480.4 | 829.9 | 222.3 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | -126.17 | -126.2 | 115.2 | -11.1 | ||||||||||||||||||
income-statement-row.row.net-income | -783.26 | -783.3 | 727.4 | 240.8 |
Dažnai užduodami klausimai
Kas yra Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) bendras turtas?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) bendras turtas yra 19203415131.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 2721572551.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.325.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.159.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.144.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.124.
Kas yra Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -783258039.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 5562816036.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 1935358054.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 1851642224.000.